Incidence and Prognosis of COVID-19 in Patients with Psoriasis: A Multicenter Prospective Study from the Eastern Black Sea Region of Turkey

Baykal Selcuk L., Aksan B., Kulakli S., Oguz I. D., Gündogdu M., Dere G., ...Daha Fazla

Acta Dermatovenerologica Croatica, cilt.30, sa.4, ss.209-215, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 4
  • Basım Tarihi: 2022
  • Dergi Adı: Acta Dermatovenerologica Croatica
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE
  • Sayfa Sayıları: ss.209-215
  • Anahtar Kelimeler: biologic, comorbidity, COVID-19, non-biologic systemic drugs, psoriasis
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

COVID-19 infection can have a poor prognosis, especial-ly in patients with chronic diseases and those receiving immunosup-pressive or immunomodulating therapies. This study aimed to investigate the severity of COVID-19 infection in patients with psoriasis and compare the infection severity for systemic treatments and comorbidities. We conducted a study in the dermatology clinics of five different centers in the Eastern Black Sea region of Turkey. Four hundred and eighty-eight patients were included, and 22.5% were confirmed as having COVID-19 infection. In our study, the frequency of hospitalization rates due to COVID-19 infection were similar (15.4%, 25.9% respectively) in patients receiving biological treatment and receiving non-biological systemic treatment (P=0.344). Hospitalization rates were higher in patients with hypertension, androgenetic alopecia, and acitretin use (P=0.043, P=0.028, P=0.040). In conclusion, current biologic treatments and non-biologic systemic treatments in patients with psoriasis did not appear to increase the risk of the severe form of COVID-19, except for acitretin.